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ABSTRACT
The Small Molecule Pathway Database (SMPDB) is
an interactive, visual database containing more than
350 small-molecule pathways found in humans.
More than 2/3 of these pathways (>280) are not
found in any other pathway database. SMPDB is
designed specifically to support pathway elucida-
tion and pathway discovery in clinical metab-
olomics, transcriptomics, proteomics and systems
biology. SMPDB provides exquisitely detailed,
hyperlinked diagrams of human metabolic
pathways, metabolic disease pathways, metabolite
signaling pathways and drug-action pathways. All
SMPDB pathways include information on the
relevant organs, organelles, subcellular compart-
ments, protein cofactors, protein locations, metab-
olite locations, chemical structures and protein
quaternary structures. Each small molecule is
hyperlinked to detailed descriptions contained in
the Human Metabolome Database (HMDB) or
DrugBank and each protein or enzyme complex is
hyperlinked to UniProt. All SMPDB pathways are
accompanied with detailed descriptions, providing
an overview of the pathway, condition or processes
depicted in each diagram. The database is easily
browsed and supports full text searching. Users
may query SMPDB with lists of metabolite names,
drug names, genes/protein names, SwissProt IDs,
GenBank IDs, Affymetrix IDs or Agilent microarray
IDs. These queries will produce lists of matching
pathways and highlight the matching molecules on
each of the pathway diagrams. Gene, metabolite
and protein concentration data can also be visual-
ized through SMPDB’s mapping interface. All of
SMPDB’s images, image maps, descriptions and
tables are downloadable. SMPDB is available at:
http://www.smpdb.ca.
INTRODUCTION
Much of the analytical technology developed over the past
two decades to facilitate genomics, transcriptomics,
proteomics and metabolomics has been aimed at helping
to elucidate the connections between genes, proteins and
metabolites and their physiological consequences. These
connections, their processes and outcomes can usually be
summarized in pathway diagrams or pathway maps.
Indeed, pathway maps in textbooks and wall charts have
long been used to describe the basics of metabolism. They
have also proven to be valuable tools in giving some
rhyme and reason to complex and interconnected meta-
bolic processes (1). The concept of metabolic pathway
mapping has actually proven to be so eﬀective that it
has been extended to describe protein signaling, protein–
DNA interactions and many other molecular biological
phenomena.
Perhaps the ﬁrst molecular pathway resource to gain
wide popularity was a paper wall chart developed by
Dr. Gerhard Michal, a staﬀ scientist at Boehringer
Mannheim (now Roche Applied Sciences), and published
in 1968 (2). This richly annotated and compactly illus-
trated poster depicts most of the known metabolic
pathways, metabolites and enzymes associated primarily
with eukaryotic metabolism. It has been revised and
expanded many times since its ﬁrst release and has
proven to be very popular, with more than 1 million
copies now in print. With the development of the World
Wide Web along the growing interest in systems biology
(3) and model organism pathways (4), the utility of wall
charts has diminished somewhat and a substantial shift
has been made to displaying this information through
web-accessible pathway charts and pathway databases.
Over the past decade, a number of superb, web-accessible
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Kyoto Encyclopedia of Genes and Genomes (KEGG)
(5), the ‘Cyc’ databases (6,7), the Reactome database (8),
WikiPathways/GeneMAPP (9), the Edinburgh Human
Metabolic Network (EHMN) (10), PharmGKB (11), the
Medical Biochemistry Page (http://themedicalbiochem
istrypage.org/) and PathwayCommons (http://www
.pathwaycommons.org). Several companies have also
created beautifully illustrated, freely available pathway
databases such as BioCarta (www.biocarta.com), Cell
Signal pathways (www.cellsignal.com), Sigma-Aldrich
pathways (http://www.sigmaaldrich.com/life-science/cell-
biology/learning-center/) Ambion pathways (http://www
.ambion.com), Calbiochem/Merck pathways (http://
www.merckbiosciences.co.uk) and ProteinLounge (http://
www.proteinlounge.com/). A number of commercial
pathway databases also exist, such as TransPath (from
BioBase Inc.), PathArt (from Jubilant Biosys Inc.),
MetaBase (from GeneGo Inc.) and Ingenuity Pathways
Analysis (Ingenuity Systems Inc.), many of which
provide impressive numbers of molecular pathway
diagrams.
Almost all of the above-mentioned databases con-
tain a mix of metabolic, cell signaling and disease
pathways. A few, such as KEGG, the ‘Cyc’ databases
and Reactome, have a much greater emphasis on small-
molecule interactions (i.e. metabolism) while most of the
company-generated databases place a greater emphasis
on protein–protein interactions (i.e. signaling pathways).
Most pathway databases maintain data on a large number
of diﬀerent organisms (microbes to plants to animals),
while a small number are very organism speciﬁc (The
Medical Biochemistry Page, EcoCyc). Some pathway
resources such as KEGG and Reactome use pathway
diagrams that are very generic and highly schematic or
simpliﬁed, while still others use diagrams that very
speciﬁc and rich in detail, color and content (BioCarta,
ProteinLounge, Ambion). Most of these web-based
databases support interactive image mapping with
hyperlinked information content that can range from
very sparse (most of the open-access company databases)
to moderately detailed (KEGG, Reactome, the ‘Cyc’
databases). Almost all of the databases support some
kind of limited text search and a few, such as Reactome,
Pathway Commons and the ‘Cyc’ databases, support the
mapping of gene, protein and/or metabolite expres-
sion data onto pathway diagrams. Overall, the quality,
coverage and capability of today’s molecular pathway
databases are quite impressive and they are frequently
used in studies relating to proteomics, systems biology,
metabolic engineering and metabolomics. However, all is
not well in the pathway database ﬁeld.
Over the past few years, our group has been actively
involved in clinical metabolomics (12,13) and in
developing a number of clinical metabolomics databases,
including DrugBank (14), the HMDB (15) and the T3DB
(http://www.t3db.org). In the course of this work, we have
used or become very familiar with many of the pathway
resources described above. Unfortunately, with respect to
clinical metabolomics (i.e. human metabolism, human
diseases and drug therapy), we have found that none of
the pathway databases mentioned above has the depth or
breadth of information needed to be truly eﬀective in this
particular area of research. This situation is certainly
understandable given that most pathway databases were
developed before the advent of metabolomics or without
the intent of creating a resource speciﬁcally for clinical
metabolomics.
Ideally, what is needed for clinical metabolomics is
a pathway database that focuses on small molecules only
and which provides large numbers (>300) of detailed,
hyperlinked diagrams of human metabolic pathways,
metabolic disease pathways, metabolite signaling
pathways and drug-action or drug-metabolism
pathways. To be truly useful, these pathway diagrams
need to include information on the relevant organs,
organelles, subcellular compartments, protein cofactors,
protein locations, metabolite locations, chemical struc-
tures and protein quaternary structures. Each small
molecule, gene or protein shown in each pathway
diagram should hyperlinked to detailed descriptions as
well as relevant clinical information and all pathways
should be accompanied with overviews describing the
corresponding pathway, condition or processes. The
database should be easily browsed and must support full
text, structure and sequence searching. Likewise, gene,
metabolite and protein lists or concentration data should
be easily mapped to every one of the pathway diagrams.
In response to these very speciﬁc needs, we have developed
just such a database: the Small Molecule Pathway
Database (SMPDB).
DATABASE DESCRIPTION
SMPDB is a pathway database designed to facilitate
clinical ‘omics’ studies, with a speciﬁc emphasis on
clinical metabolomics. In particular, SMPD consists of
more than 350 hand-drawn pathways describing small-
molecule metabolism or small-molecule processes that
are speciﬁc to humans. More than 280 of these are
unique to SMPDB and are found nowhere else. These
pathways fall into four diﬀerent categories: (i) metabolic
pathways; (ii) small-molecule disease pathways; (iii) small-
molecule drug pathways; and (iv) small-molecule signal-
ing pathways. In determining whether a small-molecule
pathway or process is suitable for inclusion in SMPDB,
the pathway must be found in humans and it must have at
least ﬁve small molecules (if it is a metabolic pathway)
or its central feature must be based on the action of at
least one small molecule (if it is a disease, drug or signaling
pathway).
More speciﬁcally, in SMPDB, disease pathways refer to
those pathways describing human disease processes (cause
and eﬀect) where small-molecule metabolite dysregulation
is the primary hallmark of the disease. That is, if signiﬁ-
cant concentration changes for a small molecule or set of
small molecules is commonly used for the diagnosis, prog-
nosis or monitoring of a given disease, then it qualiﬁes for
inclusion in SMPDB. For example, most inborn errors
of metabolism (i.e. phenylketonuria) qualify for inclu-
sion into SMPDB. Likewise diseases such as diabetes,
Nucleic Acids Research, 2010,Vol.38, Database issue D481metabolic syndrome, hyperlipidemia, various endocrine
disorders as well as several kidney, liver and gastrointes-
tinal disorders would also qualify. On the other hand,
most cardiovascular diseases, pulmonary diseases, infec-
tious diseases, cancers and many neuromuscular diseases
would not. In a similar vein, drug pathways in SMPDB
are deﬁned as those pathways describing either the metab-
olism or mode of action of small-molecule drugs at
a molecular, cellular or physiological level. Likewise,
signaling pathways in SMPDB are deﬁned as those
pathways or physiological processes where signaling
events are primarily mediated by small-molecule metab-
olites as opposed to proteins. This would include process
such as neural or synaptic transmission, muscle activation,
second-messenger signaling and small-molecule endocrine
signaling. SMPDB signaling pathways would therefore
not include most protein- or phosphoprotein-mediated
signaling events.
An example of a typical SMPDB pathway (bile acid
biosynthesis) is shown in Figure 1. As seen in this ﬁgure,
all SMPDB pathways explicitly include the chemical struc-
ture of the major metabolites (or drugs) in each pathway.
In addition, the cellular locations (membrane, cytoplasm,
extracellular, mitochondrion, nucleus, peroxisome, etc.)
of all metabolites and the enzymes or proteins involved
in their processing are explicitly illustrated. Likewise, the
quaternary structures (if known) and cofactors associated
with each of the pathway proteins are also shown. If some
of the metabolic processes occur primarily in one organ or
in the intestinal microﬂora (as in bile acid biosynthesis),
these features are also illustrated. We believe the inclusion
of this ‘structural’ information (i.e. cellular, chemical and
physiological) is one of the more unique and useful
features of SMPDB. In particular, this kind of informa-
tion provides both context and clarity to a number of
metabolic processes that are highly dependent on certain
key organs, organelles or chemical frameworks.
The SMPDB interface is largely modeled after the
interface used for DrugBank (14) and the HMDB (15),
with a navigation panel for browsing, searching and
downloading the database. Below the navigation panel is
a simple text query box that supports general text queries
of the entire textual component of the database. Mousing
over the Browse button allows users to choose between
two browsing options, SMP-BROWSE and SMP-TOC.
SMP-TOC is a scrollable hyperlinked table of contents
that lists all pathways by name and category. SMP-
BROWSE is a more comprehensive browsing tool that
provides a tabular synopsis of SMPDB’s content using
thumbnail images of the pathway diagrams, textual
descriptions of the pathways, as well as lists of the corre-
sponding chemical components and enzyme/protein
components. This browse view allows users to casually
scroll through the database, select diﬀerent pathway
categories or re-sort its contents. Clicking on a given
thumbnail image or the SMPDB pathway button brings
up a full-screen image for the corresponding pathway.
Once ‘opened’ the pathway image may be expanded by
clicking on the Zoom button located at the top and
bottom of the image or the magnifying-glass icons in
the Highlight/Analyzer box on the right of the image.
A pathway legend link is also available above the Zoom
button. At the top of each image is pathway synopsis
contained in a yellow box, while at the bottom of each
image is a list of references. On the right of each pathway
image is a gray–green Highlight/Analyzer tool with a list
of the key metabolites/drugs and enzymes/proteins found
in the pathway. Checking on selected items when in the
SMP-Highlight mode will cause the corresponding
metabolite or protein in the pathway image to be high-
lighted with a red box. Entering concentration or relative
expression values (arbitrary units) beside compound or
protein names, when in the SMP-Analyzer mode, will
cause the corresponding metabolites or proteins to be
highlighted with diﬀering shades of green or red to illus-
trate increased or decreased concentrations.
As with most pathway databases, all of the chemical
structures and proteins/enzymes illustrated in SMPDB’s
diagrams are hyperlinked to other online databases or
tables. Speciﬁcally, all metabolites, drugs or proteins
shown in the SMP-BROWSE tables or in a pathway
diagram are linked to HMDB, DrugBank or UniProt
(16), respectively. Therefore, clicking on chemical or
protein image will open a new browser window with the
corresponding DrugCard, MetaboCard or UniProt table
being displayed. By hyperlinking to these particular
databases, SMPDB is able to provide considerably more
information about its small molecules and its proteins
than any other pathway database. Indeed, SMPDB’s
UniProt links provide an average of 40 data ﬁelds about
each protein, including nomenclature, function, reaction
and structural information, while SMPDB’s DrugBank/
HMDB links provide an average of 100 data ﬁelds
about each compound, including detailed descriptions,
extensive nomenclature information, comprehensive
physico-chemical data, reference NMR and MS spectra
as well as extensive information about tissue or bioﬂuid
locations and concentrations.
SMPDB’s Search menu oﬀers users a choice of
searching the database by chemical structure
(ChemQuery), text (TextQuery), sequence (Sequence
Search) or multiple identiﬁers (SMP-MAP). The
ChemQuery option allows users to draw (using
MarvinSketch applet) or write (using a SMILES string)
a chemical compound and to search SMPDB for drugs
and metabolites similar or identical to the query
compound. The TextQuery button supports a more
sophisticated text search (partial word matches, case
sensitive, data ﬁeld selection, Boolean text searches,
misspellings, etc.) of the text portion of SMPDB. The
Sequence Search button allows users to conduct
BLASTP (protein) sequence searches of the protein
sequences contained in SMPDB. Both single and
multiple sequence BLAST queries are supported. The
most powerful search option in SMPDB is SMP-MAP,
which oﬀers both multi-identiﬁer searches as well as
‘Omic’ (transcriptomic, proteomic or metabolomic)
mapping. Through a pull-down menu located at the top
of the query textbox, SMP-MAP allows users to select the
type of ‘Omic’ data (chemical names, HMDB IDs,
DrugBank IDs, KEGG IDs, gene names, protein
names, UniProt IDs, GenBank IDs, Agilent IDs or
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to have a table generated of appropriately highlighted
pathways containing those components. The input lists
may be pasted into the search box in a single column
(name or identiﬁers only) or a double column
(identiﬁers+concentration data) format. The resulting
table, like the SMP-BROWSE table, displays a thumbnail
image of the matching pathways along with the list of
matching components (metabolites, drugs, proteins, etc.).
The table is ordered by the number of matches and a
signiﬁcance score (calculated via a hypergeometric
function), with the pathway having the most matches
being at the top. Clicking on the thumbnail image or the
SMPDB pathway button brings up a full-screen image
for the corresponding pathway with all the matching
components (metabolites, drugs, proteins, etc.) high-
lighted in red. Concentration data are displayed
using a red-to-green gradient-color intensity scheme.
Figure 1. A screenshot of the Bile Acid Biosynthesis Pathway from SMPDB. This ﬁgure illustrates the typical design and layout of an SMPDB
pathway diagram with the chemical structures, protein quaternary structures, cofactors, cellular locations, cellular structures and key organs all being
explicitly shown.
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Analyzer tool located beside the pathway image.
Through SMP-MAP, SMPDB is able to support
pathway elucidation and pathway discovery in a variety
of clinical ‘omics’ studies. For instance, users may
assemble lists of signiﬁcantly altered metabolites (or
metabolite identiﬁers), genes (or gene identiﬁers) or
proteins (or protein identiﬁers) from clinical metabolomic,
microarray or proteomic studies. The resulting lists, scores
and color-coded pathways can allow the identiﬁcation or
diagnostic conﬁrmation of certain diseases, the association
of certain ‘omic’ signatures with speciﬁc pathways or
the discovery of pathway and/or disease associations
that had not previously been detected. By allowing users
to explore each high-scoring pathway individually,
SMP-MAP may also allow new biochemical insights to
be gained or suggest new conﬁrmatory clinical tests to
be performed.
In addition to the Browse and Search options, SMPDB
also oﬀers background data, citation information,
references, links to other databases and statistical infor-
mation under its ‘About’ menu. Users may also download
sequence data, structure data and all of the image pathway
data (as PowerPoint or JPG) images by navigating
through the ‘Download’ menu.
QUALITY ASSURANCE AND CURATION
Each pathway diagram in the SMPDB is initially drawn
using Microsoft PowerPoint using a palette of specially
drawn icons to facilitate consistent illustration of organs,
membranes, organelles, DNA, RNA, proteins, protein
complexes, co-factors and chemical structures. A legend
showing all of the standard SMPD icons and their
meanings is given under the ‘About’ section in the
SMPDB menu bar. Once drawn, the pathway image is
converted to a JPG format and the chemical structures,
proteins and co-factors are manually image mapped using
the DreamWeaver software package. Three diﬀerent-sized
JPG images are prepared to facilitate rapid and consistent
image zooming. All protein names, metabolite names,
drug names, UniProt IDs, HMDB IDs and DrugBank
IDs associated with each pathway are entered into a
MySQL database to facilitate searching and hyperlinking.
All pathways in the SMPDB have been drawn using a
standard operating procedure (SOP) with a checklist of
features that each of the pathway artists and pathway
annotators were required to follow. This SOP and check-
list is also provided in the ‘About’ menu. To ensure that
the pathways have been knowledgably illustrated, all
of the SMPDB pathway artists and annotators were
required to have degrees in biology, biochemistry or
bioinformatics. To check that the pathway illustrations
(especially for metabolic and small molecule signaling
pathways) were as correct and as comprehensive as
possible, the SMPDB pathway artists and annotators
were also required to consult a variety of sources includ-
ing biochemistry textbooks, the Boerhinger–Manheim
wall chart (2), OMIM (17), Wikipedia, KEGG (5),
HumanCyc (7), Reactome (8), the Medical Biochemistry
Page, UniProt (16), the HMDB (15), DrugBank (14) and
PharmGKB (11). This allowed the annotation team to
identify and consolidate pathway nomenclature, key
pathway components, critical reactions, cellular compart-
ments and key organs or organelles. Inconsistencies and
errors were resolved by comparing data from multiple
sources or ﬁnding review papers that clariﬁed the situa-
tion. Pathway layouts were also assessed, compared and
discussed by SMPDB team members prior to manually
generating any pathway diagrams. Because of the unique
rendering requirements and the strict SOPs for SMPDB,
no pathway in SMPDB could be ‘copied’ from any other
pathway diagram in any other database.
Because of the dearth of online drug and disease
pathways, SMPDB’s metabolic disease pathways and
drug pathways were generated independently of any
pathway database. Instead, relevant information was
gathered from various medical and pharmacology text-
books, relevant encyclopedias, as well as several online
databases such as OMIM (17) and DrugBank (14). This
textual data were used to both design and render the
pathway diagrams. The same SOPs for generating the
metabolic and metabolite signaling pathways were used
for generating SMPDB’s disease and drug pathways.
Reference information for every SMPDB pathway is
provided in the pathway description textbox located
below each pathway image. As an additional layer of
quality assurance, all of the pathway diagrams in the
SMPDB have been inspected and corrected by two or
more curators having PhDs in biochemistry or physiology.
UNIQUE FEATURES AND COMPARISONS TO
OTHER PATHWAY DATABASES
While there are several well-known metabolic pathway
databases (KEGG, HumanCyc, Reactome, BioCarta,
etc.), we have generally found that for the purposes of
clinical ‘omics’ studies, the display formats, query
options, information content and pathway coverage in
these databases were often insuﬃcient, sometimes incor-
rect or occasionally absent. In developing SMPDB, we not
only tried to improve upon these shortcomings but also
to build on some of the strengths of existing databases.
We also endeavored to add content that is not normally
found in other pathway databases. In particular, of the
364 pathways in SMPDB, 281 (or 72% of SMPDB’s
content) are unique. More speciﬁcally, 11/13 metabolite
signaling pathways, 4/70 metabolic pathways, 154/168
drug pathways and 112/113 metabolic disease pathways
depicted in SMPDB are not depicted in any form by
KEGG, Reactome, EHMN, WikiPathways, HumanCyc,
BioCarta, PharmGKB or any other database. Indeed,
SMPDB is currently the only pathway database that
includes signiﬁcant numbers of metabolic disease
pathways (>110) and drug pathways (>160). In addition
to providing a large number of novel pathways, SMPDB
also adds a signiﬁcant amount of new information
content, including more than 30000 words of original
text describing each pathway in the context of human
physiology and human biochemistry. Furthermore,
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detailed descriptions of that molecule, including extensive
nomenclature information, comprehensive physico-
chemical data, thousands of reference nuclear magnetic
resonance (NMR) and mass spectrometry (MS) spectra
as well as extensive information about tissue or bioﬂuid
locations and concentrations (100 data ﬁelds per
compound). In addition to this textual content, SMPDB
also oﬀers a signiﬁcant amount of new and useful
graphical content, including the depiction of the relevant
organs, cellular locations, organelles, membrane
boundaries, protein quaternary structures, cofactors and
other cellular features in its pathway diagrams.
With regard to its interface design, SMPDB also oﬀers
a number of new or unique features. In particular,
SMPDB uses thumbnail images to facilitate pathway
viewing and browsing, it uses a scrollable table to
display pathways and pathway synopses, and it employs
a unique checkbox Highlight/Analyzer tool to allow users
to interactively highlight and color multiple metabolites,
drugs and/or proteins on its pathway images. SMPDB
also uses a graphical structure-searching applet to enable
sophisticated drug or metabolite similarity searches.
As with some of the more fully developed pathway
databases, SMPDB also provides protein/metabolite lists
for each pathway, it supports advanced text and sequence
queries and it allows pathway mapping from protein,
gene and metabolite lists. While space does not permit
a detailed comparison against all existing pathway
databases, it is perhaps instructive to compare SMPDB
to six of the larger and more established resources:
KEGG, Reactome HumanCyc, BioCarta, EHMN and
WikiPathways/GenMAPP.
This comparison is summarized in Table 1 where we
have used a number of general features or criteria to
make our assessment. Some of these criteria deﬁnitions
may need further elaboration. In particular: ‘Information
provided on pathway entities’ is deﬁned as providing
hyperlinks to pages that give additional detail on
protein/drug/metabolite sequences, functions, properties,
reactions, structure, concentrations or spectra. ‘Supports
advanced text search’ is deﬁned as supporting ﬁeld-speciﬁc
searches, wild-card queries, Boolean searches, synonym
searches, mis-spellings, text sorting or other kinds of
complex textual queries beyond simple text matching.
‘Component lists available’ is deﬁned as providing easily
accessed, plain text or hyperlinked textual lists of all the
genes, proteins, drugs and/or metabolites displayed in
the pathway. In addition to the information in Table 1,
we have also elaborated on the comparisons for four of
the databases (KEGG, HumanCyc, Reactome and
BioCarta) in the following paragraphs.
KEGG, with 330 reference pathways, is considered to
be the ‘gold standard’ for most pathway databases
because of its comprehensiveness and its breadth of
organism-speciﬁc coverage. Of KEGG’s 158 metabolic
pathways (Table 1), 73 are relevant to humans or other
mammals. Interestingly, several key metabolic pathways
in mammals are actually missing from KEGG (i.e. the
malate-aspartate shuttle, and electron transfer). As the
pathway diagrams in KEGG are designed to be very
‘generic’ they display no organ data, no cellular structure
information, no protein superstructure data, no chemical
structure information (except through hyperlinks) and no
gene or protein names (only EC numbers). While KEGG
does have 35 disease pathways, most are for cancer,
neurological or immune diseases and only three of these
relate to small-molecule metabolites or metabolic diseases.
KEGG’s drug pathways are limited to showing only drug
development or drug similarity as opposed to drug action
Table 1. Comparison of SMPDB to KEGG, HumanCyc, Reactome, BioCarta, EHMN and WikiPathways/GenMAPP
Feature SMPDB KEGG Reactome HumanCyc BioCarta EHMN WikiPathways
Number of metabolic pathways 70 73 (for
humans)
64 (for
humans)
317 (total),
238 (conf)
55 70 44 (for
humans)
Number of disease pathways 113 35 3 0 24 0 4
Number of drug action pathways 168 0 3 3 10 0 4
Provides multiple organism pathways No Yes Yes No Yes No Yes
Chemical structures shown in diagrams Yes No Some Yes (when
zoomed)
Some No No
Protein 4 structures shown in diagrams Yes No No No Some No No
Cell structures shown in pathway diagrams Yes No No No Yes No No
Organs shown in pathway diagrams Some No No No No No No
Descriptions of pathways provided Yes No Yes Yes Yes No Some
Pathway images are hyperlinked Yes Yes Limited Yes Yes No No
Pathway images are zoomable Yes No No Yes No Yes Limited
Information provided on pathway entities Detailed Modest Limited Moderate Limited Limited Limited
Supports simple text search Yes Yes Yes Yes No Yes Yes
Supports advanced text search Yes No Yes Yes No No No
Supports sequence searching Yes No No Yes No No No
Supports graphical chemical structure search Yes No No No No No No
Supports chemical expression mapping Yes No Yes Yes No No No
Supports gene/protein expression mapping Yes No Yes Yes No No No
Downloadable Yes Yes Yes Yes No No Yes
Component lists available Yes No Yes No Proteins only Yes Yes
BioPax, CellML or SBML compatible No Partial Yes Yes No Yes No
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useful annotations (via hyperlinks) for the compounds
shown in its pathways, it does not provide descriptive
summaries of these pathways nor does it support the
visual display of gene/protein/metabolite concentrations.
As yet, KEGG does not provide protein/metabolite lists
for each pathway nor does it support graphical structure
queries or chemical structure similarity searches.
Similar to KEGG, the Reactome database provides
1000s of metabolic and signaling pathway data sets for
many model organisms. Of these, 64 pathways are
associated with human metabolism, three with human
diseases and three with drug action or drug metabolism.
Through its Reaction Map interface, Reactome is able to
provide users with low-resolution pathway maps (similar
to the thumbnail images used by the SMPDB browser)
that allow users to interactively navigate through the
database. Like SMPDB, Reactome provides extensive
pathway or reaction descriptions along with hyperlinks
to several external databases. Unlike SMPDB, Reactome
does not display organ data, cellular compartment data,
cellular organelle information, protein complex informa-
tion or protein/gene names in its pathway diagrams.
Likewise, Reactome has very few disease or drug
pathways. On the other hand, Reactome, like SMPDB,
has a ‘Skypainter’ feature allows users to paste in a list
of genes or gene identiﬁers and to ‘paint’ the Reactome
reaction map in a variety of ways. Unlike SMPDB,
Reactome does not support chemical structure or
sequence queries.
The HumanCyc database contains 349 pathways,
including 29 superpathways (supersets of many of the
other 320 pathways in the database). Two hundred and
thirty-eight of these pathways are conﬁrmed, meaning
they have ‘evidence glyphs’ indicating 50% or more of
the reactions have some evidence of occurring in
humans. All pathways in HumanCyc can be ‘zoomed-in’
to display chemical structures, EC numbers and pro-
tein names, similar to SMPDB. Similar to SMPDB,
HumanCyc supports advanced text searches as well as
sequence searches. HumanCyc’s metabolic pathways are
well referenced and generally well described, although
most descriptions are given in the context of bacterial
or plant metabolism. The images in HumanCyc do not
display organ data, cellular compartment data, cellular
organelle information or protein complex information.
Currently, HumanCyc does not have any disease
pathways and it provides only three drug pathways.
While HumanCyc does support the visual display of
gene/protein/metabolite concentrations using its own
‘OmicsViewer’, the display is small and sometimes diﬃcult
to interpret—especially for metabolomics applications.
Unlike SMPDB, HumanCyc does not provide protein/
metabolite lists for each pathway nor does it support
chemical structure similarity searches.
The BioCarta database, with 360 pathways, is proba-
bly the most visually sophisticated database of the four
pathway databases described here. Like SMPDB, not only
most of its pathways depict cell, protein and chemical
structure information, but also all of its pathways
are well annotated with very detailed descriptions.
BioCarta also contains a large number (>250) of protein
signaling pathways and many other macromolecular inter-
action processes. However, BioCarta only has a modest
number (55) of pathways that are devoted to small
molecule metabolism and an even smaller number (<35)
of pathways that are devoted to disease or drug action
pathways. Very few of these disease or drug pathways
overlap with those in SMPDB. As BioCarta is a
community-annotated/generated database, its collection
of pathways is somewhat haphazard and largely depen-
dent on community interest. Likewise, BioCarta’s
querying and display tools are very limited compared to
most other pathway databases.
LIMITATIONS AND FUTURE PROSPECTS
Compared to most other pathway databases, SMPDB
is really a niche database that is speciﬁc to just one
(albeit important) organism—namely humans. In this
regard, SMPDB certainly lacks the breadth of metabolic
coverage oﬀered by KEGG, Reactome or the ‘Cyc’ family
of databases. Likewise, because SMPDB is focused on
small molecules, it does not include the key protein
signaling pathway information found in other databases,
such as KEGG, BioCarta or TransPath. As a conse-
quence, SMPDB is not—nor will it ever be—very useful
for those interested in comparative metabolic studies,
protein network analysis, metabolic engineering, protein
signal transduction or metabolic evolution. Because of its
narrow focus and restricted mandate, SMPDB should not
be thought of as a replacement for existing pathway
databases. Rather, the information in SMPDB should be
viewed as complementary to what is already out there.
While SMPDB is essentially a database of small-
molecule pathways, it is also a database of scientiﬁc
artwork. The art, in this case, corresponds to our best
understanding and our best eﬀorts at representing the
complex chemical and biochemical processes found in
humans. As such, SMPDB is not without ﬂaws.
Certainly, with any illustration or piece or art, there are
other (potentially better) ways of rendering the process or
in capturing its essence. Likewise, because art is very much
a personal choice, it is likely that the style, layout and
color scheme adopted by SMPD may not agree with
every user. For instance, the display of all chemical
structures (which vary widely in size) may make some
SMPDB pathway images a little diﬃcult to interpret.
However, because SMPDB is primarily designed to serve
the metabolomics community, this made chemical struc-
ture rendering an essential part of its construction. Other
aspects, such as the use of a dark blue background
(to represent aqueous conditions) and thin directional
arrows (to reduce clutter), may not appeal to all users.
However, the fact that all of SMPDB’s PowerPoint
images are downloadable, certainly should allow users to
re-render or re-color the pathways to their liking.
While considerable eﬀort and many revisions went
into developing both the current pathways and standard
pathway drawing protocols, SMPDB is far from uniform.
It is worth noting that SMPDB was assembled from
D486 Nucleic AcidsResearch, 2010, Vol.38,Database issuemultiple artists, and this means there will always be some
inconsistency in how data are schematically represented
and how much detail is displayed in any given ﬁgure.
Again, these issues can be addressed if users provide
feedback to SMPDB’s annotation team or if they choose
to download and edit SMPDB images on their own.
Another important limitation to SMPDB is the fact that
its pathways are not (yet) represented in BioPax or SBML
format (18). Eﬀorts will be made in the future to convert
most SMPDB images to SBML and SimCell (19) compat-
ible formats, but it is important to note that SMPDB was
designed to be more of a human-readable database rather
than a machine-readable resource. Consequently, most of
our computational eﬀort has gone into to providing
powerful searching, querying and viewing tools to facili-
tate user interactivity.
Like many existing pathway databases, SMPDB is still
a work in progress. We are currently adding two to three
new pathways a week and are constantly revising or
improving the renderings of existing pathways images
based on new data or on user feedback. While the
number of metabolic pathways is unlikely to change sub-
stantially, it is expected that the total number of disease
and metabolic signaling pathways will eventually exceed
200, and the number of drug action pathways will cer-
tainly exceed 400. In addition, to the planned expansion
in size, SMPDB’s metabolic and disease pathways will
be formally linked to the next release of the HMDB,
while its drug action pathways will be linked the next
release of DrugBank. SMPDB is also being integrated
into a virtual reality ‘CAVE’ environment for interactively
visualizing and modeling human metabolism (20). Overall,
we believe SMPDB is a useful addition to the current col-
lection of pathway databases and we are hopeful that
some of its more innovative or useful ideas will eventually
ﬁnd their way into other online pathway databases.
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